Increased regulatory scrutiny of foreign direct investments in the healthcare sector

Published date29 July 2020
Subject MatterMergers,Medical Devices,CFIUS,European Commission,EU,Biotechnology,Cross-Border Transactions,Healthcare Facilities,Threshold Requirements,Critical Infrastructure Sectors,Canada,Voting Rights,UK,Australia,Japan,New Zealand,Foreign Direct Investment,France,Spain,Italy,Poland,Austria,Member State,Czech Republic,Hungary,Pharmaceutical Industry,Foreign Acquisitions,Slovenia,Coronavirus/COVID-19
AuthorAlec Burnside,Thirith von Döhren,Michael Okkonen,Sophie Pelé,Marjolein De Backer,Delphine Strohl,Robert Darwin,Sophie Mitouard
Law FirmDechert LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT